metformin + vitamin D + calcium

Metformin + vitamin D + calcium is a combination of three agents commonly used in clinical and research settings, particularly for metabolic and endocrine disorders. Metformin is an oral antihyperglycemic agent that primarily acts by decreasing hepatic glucose production and improving insulin sensitivity. Vitamin D (typically as cholecalciferol or ergocalciferol) is a fat-soluble vitamin essential for calcium homeostasis, bone health, and modulation of immune function; it acts via the vitamin D receptor to regulate gene expression. Calcium is a mineral critical for bone structure, neuromuscular function, and various cellular processes. This combination has been studied in several contexts: - In polycystic ovary syndrome (PCOS), the addition of calcium-vitamin D to metformin therapy has shown improved outcomes in menstrual regularity, follicular maturation, and ovulation compared to individual treatments[6][8]. - In nonalcoholic fatty liver disease (NAFLD) models, co-supplementation with metformin plus calcium-vitamin D3 reduced hepatic steatosis more than either alone but did not show marked additional benefits over monotherapy[1]. - Preclinical studies suggest synergistic effects on osteogenic differentiation under high-glucose conditions[5] and enhanced chemopreventive activity against early colon neoplasia through AMPK/mTOR pathway modulation[2]. The mechanism of action involves: - Metformin activating AMP-activated protein kinase (AMPK), reducing gluconeogenesis. - Vitamin D binding to the vitamin D receptor (VDR), influencing gene transcription related to cell growth/differentiation. - Calcium supporting bone mineralization and acting as a secondary messenger in cellular signaling. No unique brand or code name exists for this specific triple combination; it may be compounded or prescribed as separate agents taken together.